U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
8.07+0.25 (+3.20%)
At close: 04:00PM EDT
8.06 -0.01 (-0.12%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.82
Bid8.11 x 21500
Ask8.12 x 36900
Day's Range7.85 - 8.24
52 Week Range6.78 - 11.34
Avg. Volume13,401,522
Market Cap8.901B
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-3.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est10.07
  • Motley Fool

    Why Teva Stock Shot More Than 3% Higher Today

    Teva Pharmaceutical Industries (NYSE: TEVA) stock closed the trading week in style, rising by over 3% on a bleak and bearish day for the wider market. Teva Pharmaceuticals, the company's key subsidiary, has reached an agreement with the southern state's attorney general to settle accusations of price-fixing. Under the terms of the arrangement, Teva is to pay just under $3.35 million; in return, once the funds are handed over Georgia will dismiss all claims against the company in the case.

  • Business Wire

    Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

    TEL AVIV, Israel & PARSIPPANY, N.J., September 30, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.

  • Benzinga

    European Drug Makers Say Higher Energy Costs Eating Margins: Report

    Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novartis AG's (NYSE: NVS) Sandoz unit, and Fresenius SE's (OTC: FSNUY) Kabi business, sent a letter to European states' energy and health ministers, asking for measures to relieve the cost burden. According to Medicines for Europe, Generic associations p